The longed-for recovery in startup exits hasn't yet arrived. But those startups that did get bought or publicly listed in September did so at higher prices.

The European venture capital firm aims to raise a total €250m for its fourth fund by next year.

The Canadian venture firm is opening an office in Asia as Asian corporations flock to invest in its fifth fund and largest fund.

Berger will lead the biotech investment for the Saudi city project, contributing to the Kingdom's goal of becoming a global biotech hub.

Ian McClure is expanding his role from associate vice president for research, innovation and economic impact at the University of Kentucky to include vice president of innovation for UK Healthcare, the institution's health system.

South Korean multinational Lotte Holdings has set up a CVC arm to invest in new technology in healthcare and biopharmaceuticals.

SEC filings show the CVC wants to raise its third nine-figure fund to back biotech startups.

Female-focused health startups have been receiving increased funding in 2024 and a new crop of startups is emerging to address previously underserved areas.

Maarten-Yan Wierenga is serving as interim head of NuFrontiers while Erik Tveteraas joined fungus-based protein developer NoMy as CFO.

Private equity companies have been active in buying VC-backed companies, sometimes at a significant discount. Digital and life sciences startups dominate the list of exits.